Skip to main content
Clinical Trials/NCT00828945
NCT00828945
Completed
Not Applicable

A Non-Randomized, Non-Controlled, Open Study In Order To Document The Compliance With Treatment, According To Clinical Praxis And National Guidelines For Patients With Hyperlipidemia. COLL: Control Of Lipid Lowering

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 site in 1 country259 target enrollmentFebruary 2009
ConditionsHyperlipidemia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Hyperlipidemia
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Enrollment
259
Locations
1
Primary Endpoint
Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

It is a prospective observational study.

Patients will be high risk patients (for developing cardiovascular events) that are treated with a statin. Patients will be enrolled at a normal clinic visit and provided with a small box containing info about the disease, a LDL self-test and two questionnaires. They will test themselves for LDL at home between normal clinic visits (normally 12 months interval) and note their value. In the end of the study all patients will fill out a questionnaire with questions if the tests and info have raised their awareness of the disease as well if their motivation to be compliant has increased.

We want to look at the possibility to put more responsibility for treatment and for reaching treatment goals on the patients since there's a big problem with compliance in this group of patients.

Detailed Description

Consecutive patient sampling

Registry
clinicaltrials.gov
Start Date
February 2009
End Date
March 2011
Last Updated
5 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years or older and able to understand and sign the informed consent form.
  • Patients diagnosed with hyperlipidemia and a very high risk developing cardiovascular disease prescribed statin treatment according to clinical praxis and the recommendations set forth in the MPA national guideline for treatment of hyperlipidemia.

Exclusion Criteria

  • Patients contraindicated for statin treatment according to market authorization for these drugs should be excluded from the study.
  • Patients participating in other clinical trials or non-interventional studies.

Outcomes

Primary Outcomes

Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12

Time Frame: Month 12

Participants with "Yes" response to a question which stated "The self-test have increased my motivation for taking my medication for hyperlipidemia?". The self test done for assessment of LDL levels using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Positive Response on Self-estimated Treatment Compliance at Month 6

Time Frame: Month 6

Participants with "Yes" response to a question which stated "Have you been taking at least 90% of your medication for hyperlipidemia?".

Percentage of Participants With LDL Lower Than 2.5 mmol/L at Month 6

Time Frame: Month 6

LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Positive Response on Increased Motivation After Awareness at Month 12

Time Frame: Month 12

Participants with "Yes" response to a question which stated "The awareness of my disease has increased my motivation for taking my medication for hyperlipidemia?".

Percentage of Participants With Positive Response on Self-estimated Treatment Compliance at Month 12

Time Frame: Month 12

Participants with "Yes" response to a question which stated "Have you been taking at least 90% of your medication for hyperlipidemia?".

Percentage of Participants With LDL Lower Than 2.5 mmol/L at Week 8

Time Frame: Week 8

LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Response Achieving Targeted LDL-cholesterol Level at Month 12

Time Frame: Month 12

Participants with "Yes" or "No" responses to a question which stated "Have you reached your target LDL-cholesterol level?". LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Positive Response on Self-estimated Treatment Compliance at Week 8

Time Frame: Week 8

Participants with "Yes" response to a question which stated "Have you been taking at least 90% of your medication for hyperlipidemia?".

Percentage of Participants With LDL Lower Than 2.5 mmol/L at Month 12

Time Frame: Month 12

LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Response Achieving Targeted LDL-cholesterol Level at Week 8

Time Frame: Week 8

Participants with "Yes" or "No" responses to a question which stated "Have you reached your target LDL-cholesterol level?". LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Percentage of Participants With Response Achieving Targeted LDL-cholesterol Level at Month 6

Time Frame: Month 6

Participants with "Yes" or "No" responses to a question which stated "Have you reached your target LDL-cholesterol level?". LDL levels were self-assessed by participants using CARE diagnostica LDL-cholesterol test.

Study Sites (1)

Loading locations...

Similar Trials